Novavax (NVAX) Income from Continuing Operations (2010 - 2026)
Novavax's (NVAX) quarterly Income from Continuing Operations came in at 9491000.0 in Q1 2026, down 101.83% year-on-year from 518646000.0 in Q1 2025, and down 154.15% quarter-over-quarter from 17527000.0 in Q4 2025.
Novavax (NVAX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Novavax's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 9491000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 101.83% year-over-year to 9491000.0 in Q1 2026; TTM through Mar 2026 was 87835000.0, a 118.35% decrease from a year earlier, with the FY2025 full-year figure at 440302000.0, up 334.83% from the prior year.
- Income from Continuing Operations slipped to 9491000.0 in Q1 2026 per NVAX's latest filing, from 17527000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 518646000.0 in Q1 2025 and bottomed at 510485000.0 in Q2 2022.
- The 5-year median for Income from Continuing Operations is 121300000.0 (2024), against an average of 56452294.12.
- Across the five-year window, Income from Continuing Operations slumped 244.49% in 2023 and surged 451.51% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 182249000.0 in 2022, then rose by 2.12% to 178389000.0 in 2023, then jumped by 54.58% to 81030000.0 in 2024, then jumped by 121.63% to 17527000.0 in 2025, then slumped by 154.15% to 9491000.0 in 2026.
- Per Business Quant, the three latest NVAX Income from Continuing Operations figures stand at 9491000.0 (Q1 2026), 17527000.0 (Q4 2025), and 202379000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Novavax | 788.01 Mn | -2.33 Mn | 108.82 Mn | -9.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.49 Mn |
| Dec 31, 2025 | 17.53 Mn |
| Sep 30, 2025 | -202.38 Mn |
| Jun 30, 2025 | 106.51 Mn |
| Mar 31, 2025 | 518.65 Mn |
| Dec 31, 2024 | -81.03 Mn |
| Sep 30, 2024 | -121.30 Mn |
| Jun 30, 2024 | 162.38 Mn |
| Mar 31, 2024 | -147.55 Mn |
| Dec 31, 2023 | -178.39 Mn |
| Sep 30, 2023 | -130.78 Mn |
| Jun 30, 2023 | 58.01 Mn |
| Mar 31, 2023 | -293.91 Mn |
| Dec 31, 2022 | -182.25 Mn |
| Sep 30, 2022 | -168.61 Mn |
| Jun 30, 2022 | -510.49 Mn |
| Mar 31, 2022 | 203.41 Mn |
| Dec 31, 2021 | -846.28 Mn |
| Sep 30, 2021 | -322.43 Mn |
| Jun 30, 2021 | -352.32 Mn |